Table 2 Five representative cases who were received combination therapy as neoadjuvant therapy
Patient No | No.1 | No.2 | No.3 | No.4 | No.5 |
|---|---|---|---|---|---|
Age | 32 | 47 | 64 | 68 | 60 |
Gender | male | male | male | male | female |
Histology | adenocarcinoma | adenocarcinoma | squamous carcinoma | adenocarcinoma | squamous carcinoma |
Clinical stage | cT4N1M1 (IVA) | cT3N1M1 (IVA) | cT4N3M0 (IIIC) | cT3N2M0 (IIIB) | cT4N2M0 (IIIB) |
Molecular aberration | EGFR 19del | EGFR 19del | EGFR 19del | EGFR L858R | EGFR 19del |
Concomitant mutations | TP53 mutation, EGFR amplification | TP53 mutation | EGFR amplification | TP53 mutation, HEBB2 and EGFR amplification | - |
PD-L1 expression | 5% | 0% | 90% | 0% | 0% |
Neoadjuvant therapy cycles | 3 | 3 | 2 | 2 | 2 |
Postoperative pathological stage | pT1cN0M0 (IA3) | pT1aN0M0 (IA1) | pT1bN0M0 (IA2) | pT1bN0M0 (IA2) | pT0N0M0 |
Postoperative pathological evaluation | MPR | MPR | MPR | MPR | CPR |